Neurocrine Biosciences Stock News

Neurocrine Biosciences <> is trading lower for the second straight session after RBC Capital Markets cut its rating to Sector Perform from Outperform, noting that the biotech

Xenon Pharmaceuticals Inc''s (NASDAQ: XENE ) collaboration to develop treatments for epilepsy with Neurocrine Biosciences Inc (NASDAQ: NBIX ) achieved a regulatory milestone, triggering a payment of $15.0 million to Xenon . The FDA accepted Neurocrine''s Full story available on Benzinga.com

Xenon Pharmaceuticals (XENE) reaches regulatory milestone to receive a payment of $15M from Neurocrine Biosciences (NBIX) under its collaboration to develop treatments for epilepsy. It

Neurocrine Biosciences, Inc. (NBIX) shares closed today at 0.2% above its 52 week low of $75.16, giving the company a market cap of $7B. The stock is currently down 11.6% year-to-date, down 32.8% over the past 12 months, and up 71.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 18.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 91.2% The company's stock price performance over the past 12 months lags the peer average by -10924.2% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is -12.3% lower than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Hepion's Lead NASH Drug Candidate Gets The Non-Proprietary Name Rencofilstat Hepion Pharmaceuticals, I

TOKYO, Japan and CAMBRIDGE, United Kingdom, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Sosei Group Corporation (Sosei Heptares; TSE: 4565) today announces that in connection with the Collaboration and License Agreement (License Agreement) with Neurocrine Biosciences, Inc. (Neurocrine Biosciences) announced 22 November 2021, the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) expired on 22 December 2021. As such, the License Agreement became effective on 22 December 2021. With completion of the applicable waiting period under the HSR Act, under the terms of the License Agreement Neurocrine Biosciences has agreed to pay Sosei Heptares an upfront payment of US$100 million, with the amount to be recognized as revenue in the fourth quarter of the financial year ending December 31, 2021.

State of New Jersey Common Pension Fund D raised its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 2.4% during the third quarter, HoldingsChannel reports. The institutional investor owned 58,900 shares of the companys stock after purchasing an additional 1,364 shares during the quarter. State of New Jersey Common Pension Fund Ds holdings in Neurocrine Biosciences [] The post Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Bought by State of New Jersey Common Pension Fund D appeared first on ETF Daily News .

Analysts expect that Neurocrine Biosciences, Inc. (NASDAQ:NBIX) will announce $0.59 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Eleven analysts have made estimates for Neurocrine Biosciences earnings, with the lowest EPS estimate coming in at $0.26 and the highest estimate coming in at $0.90. Neurocrine Biosciences reported earnings per share of []

Tenaya Therapeutics (NASDAQ:TNYA) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations. Insider and Institutional Ownership 34.7% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 95.3% []

Related Stocks: PG , T , IBM , GM , NBIX , CRM , SCHW , BLL , MET , GIS , GL , CMCSA , MMC , PKG , GPN , EQR , NXPI ,

Related Stocks: MRNA , BIIB , VRTX , ICLR , TECH , NTRA , NTLA , ALXN , NBIX , QDEL , IONS ,

Neurocrine Biosciences (NASDAQ:NBIX) had its price target upped by equities research analysts at Oppenheimer from $140.00 to $154.00 in a research note issued to investors on Wednesday, The Fly reports. The firm presently has an outperform rating on the stock. Oppenheimers price objective indicates a potential upside of 88.68% from the companys current price. Oppenheimer []

Neurocrine Biosciences (NASDAQ:NBIX)s stock had its buy rating restated by equities research analysts at HC Wainwright in a research report issued on Wednesday, Analyst Price Targets reports. They presently have a $139.00 price target on the stock. HC Wainwrights target price suggests a potential upside of 70.30% from the stocks current price. Other equities research []

Zacks Investment Research upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX) from a sell rating to a hold rating in a research note published on Wednesday morning, Zacks.com reports. According to Zacks, Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and disorders. The companys []

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-Operative Inflammation EyePoin